Hexarelin ability to increase secretion of natural Growth Hormone, most of its effects are similar to those of synthetic GH, although to a slightly lesser extent. Effects of its use include: increase in strength, growth of new muscle fibers, increase in the size of already existing muscle fibers, neural protection, joint rejuvenation, protection and healing. Also, the GH receptors in adipose (fat) tissue allow for potential fat reduction with Hexarelin use. The increase of circulating GH through Hexarelin use causes levels of Insulin-Like Growth Factor (IGF-1) to rise in the liver. IGF-1 is the prime cause of muscle growth in response to GH stimulation. There is no appetite boost with Hexarelin use (as opposed to GHRP-6’s extreme appetite increase) due to its inability to drastically increase Ghrelin levels that are responsible for added hunger and quicker gastric emptying.
In studies where Hexarelin was injected subcutaneously, Growth Hormone, measured through plasma concentrations, increased significantly and within thirty minutes of injection. GH levels decreased back to normal around four hours post injection. The GH increase, has been found to be effective up to 2mg/kg, any further increase in dose was found to be ineffective in causing a GH response.
Results showed that Hexarelin’s effect on GH stimulation tapered between weeks 4 through 16. Separating cycles by 4 week off periods, avoided the negative feedback loop and the next cycle of Hexarelin produced the same level of results as the first cycle.
Hexarelin (Hexarelin Acetate) is a synthetic hexapeptide in the growth factor family which stimulates the release of growth hormone (GH) and does not interfere with the body’s ability to produce its own GH. Structurally, Hexarelin (Hexarelin Acetate) is similar in structure to GHRP-6 but without the appetite increase because of its inability to drastically increase Ghrelin levels which is responsible for the increased appetite and quicker gastric emptying. Hexarelin is a synthetic growth hormone secretagogue made from six amino acids. It contains powerful growth hormone releasing properties in the human body. Hexarelin in studies over a certain period has shown that it reduces visceral fat. Hexarelin (Hexarelin Acetate) like other Growth Hormone Releasing Peptides is most effective synergistically when administered with GHRH such as Sermorelin or Modified GRF 1-29.
The increase of circulating GH through Hexarelin use causes levels of Insulin-Like Growth Factor (IGF-1) to rise in the liver. IGF-1 is the prime cause of muscle growth in response to GH stimulation. Users of IGF-1 typically experience increased strength and muscle mass, as well as a very pronounced fat loss. In animals, Hexarelin has been administered for longer periods. In six old beagle dogs, cella and colleagues demonstrated a decrease in Hexarelin-stimulated GH release during twice-daily sc Hexarelin therapy given for periods of 7 weeks, 4 weeks and 1 week, with no change in serum IGF-I. If the GH response to hexarelin in humans becomes appreciably attenuated after long-term administration, then this will seriously limit the potential therapeutic use of Hexarelin and similar agents. There are no data available on the GH releasing capacity of Hexarelin after long-term administration or on the effect of hexarelin-stimulated GH release on serum IGF-I and IGFBP-3 levels in normal adult subjects. Furthermore, there are few data on the GH response to Hexarelin after a period off treatment. We have, therefore, assessed the effect of 16 weeks of twice-daily sc Hexarelin therapy on the GH response to a single injection of Hexarelin and also the GH response 4 weeks after cessation of Hexarelin therapy.